EPA-540/1-86-033
                         Environmental Protection
                         Agency
     of Emergency and
Remedial Response
Washington DC 20460
Off'ce of Research and Development
Office of Health and Environmental
Assessment
Environmental Criteria and
Assessment Office
Cincinnati OH 45268
                         Superfund
vvEPA
                          HEALTH  EFFECTS  ASSESSMENT

                          FOR  TOLUENE

-------
                                            EPA/540/1-86-033
                                            September 1984
       HEALTH  EFFECTS  ASSESSMENT
                FOR TOLUENE
    U.S. Environmental Protection  Agency
     Office of Research and Development
Office of Health  and  Environmental Assessment
Environmental Criteria and Assessment  Office
            Cincinnati,  OH  45268
    U.S. Environmental Protection  Agency
  Office of  Emergency  and Remedial Response
Office of Solid Waste and  Emergency  Response
            Washington, DC  20460

-------
                                  DISCLAIMER

    This  report  has  been funded  wholly  or  1n  part by  the  United  States
Environmental  Protection  Agency under  Contract  No.  68-03-3112  to  Syracuse
Research Corporation.  It has been  subject  to  the Agency's peer and adminis-
trative review, and  1t has been  approved  for  publication as an EPA document.
Mention of  trade  names or commercial  products  does  not  constitute  endorse-
ment or recommendation for use.
                                      11

-------
                                    PREFACE
    This report  summarizes  and evaluates Information relevant  to  a prelimi-
nary  Interim  assessment of adverse  health  effects associated  with toluene.
All  estimates  of acceptable  Intakes and  carcinogenic  potency  presented  In
this  document  should be considered  as   preliminary  and reflect limited  re-
sources allocated to this  project.  Pertinent  toxlcologlc  and  environmental
data  were  located   through   on-line literature   searches  of  the  Chemical
Abstracts,  TOXLINE,  CANCERLINE  and the CHEMFATE/DATALOG  data bases.   The
basic  literature  searched   supporting   this   document  1s   current  up   to
September,  1984.   Secondary  sources of  Information have  also been  relied
upon  1n  the  preparation of  this  report  and  represent  large-scale  health
assessment  efforts   that  entail   extensive  peer  and  Agency  review.   The
following Office  of  Health and Environmental Assessment  (OHEA)  sources  have
been extensively utilized:


    U.S.  EPA.    1982a.   Health and  Environmental  Effects  Profile for
    Toluene.   Prepared  by  the  Environmental   Criteria and  Assessment
    Office,   Cincinnati, OH,  OHEA for  the  Office of  Solid  Waste and
    Emergency Response, Washington, DC.

    U.S. EPA.   1982b.   Health Effects Assessment  Document  for  Toluene.
    Environmental  Criteria   and   Assessment  Office,   Cincinnati,  OH.
    Internal draft.

    U.S.  EPA.   1983b.    Reportable Quantity for  Toluene.  Prepared by
    the  Environmental  Criteria and  Assessment  Office, Cincinnati, OH,
    OHEA  for  the Office of  Solid Waste and Emergency Response,  Wash-
    ington,  DC.

    U.S.  EPA.    1984.   Drinking  Water   Criteria  Document for  Toluene.
    Prepared  by  the  Environmental  Criteria  and  Assessment  Office,
    Cincinnati,  OH,  OHEA for  the  Office  of  Drinking  Water,  Washington,
    DC.  External Review Draft.

    U.S.  EPA.    1985.   Drinking  Water   Criteria  Document for  Toluene.
    Prepared  by  the  Environmental  Criteria  and  Assessment  Office,
    Cincinnati,  OH,  OHEA for  the  Office  of  Drinking  Water,  Washington,
    DC.  Final Draft.


    The Intent  in these  assessments  is  to suggest  acceptable  exposure levels
whenever sufficient  data were available.  Values were  not  derived or larger
uncertainty  factors  were  employed when  the variable  data  were  limited  1n
scope  tending  to  generate  conservative  (I.e.,  protective) estimates.  Never-
theless, the  interim values  presented  reflect  the relative degree of hazard
associated with exposure or risk to the chemlcal(s) addressed.
                                      111

-------
    Whenever possible, two categories  of  values  have been estimated for sys-
temic toxicants (toxicants for which  cancer  is  not the endpolnt of concern).
The  first,  the AIS  or acceptable  Intake subchronlc,  Is  an estimate  of  an
exposure  level  that  would not  be expected  to  cause adverse  effects  when
exposure  occurs during a  limited  time Interval   (I.e., for  an  Interval that
does  not  constitute a  significant portion of  the  Hfespan).   This  type  of
exposure  estimate  has not been  extensively  used or  rigorously  defined,  as
previous  risk  assessment  efforts  have  been  primarily  directed  towards
exposures from  toxicants  1n  ambient air  or water  where lifetime exposure  1s
assumed.  Animal  data  used   for  AIS  estimates  generally  Include  exposures
with  durations  of  30-90 days.  Subchronlc  human data  are  rarely available.
Reported  exposures are  usually from chronic  occupational  exposure situations
or from reports of acute accidental exposure.

    The  AIC,  acceptable  intake  chronic,  1s  similar  in  concept to  the  ADI
(acceptable  daily  intake).   It   is  an  estimate of  an exposure  level  that
would not be expected  to  cause  adverse  effects when  exposure  occurs  for  a
significant portion of the lifespan [see  U.S. EPA (1980)  for a discussion  of
this  concept].  The  AIC  Is route  specific and estimates  acceptable exposure
for a given route with  the Implicit  assumption  that exposure by other routes
is insignificant.

    Composite  scores  (CSs)   for   noncarcinogens  have  also  been  calculated
where data  permitted.   These  values are  used for  ranking reportable  quanti-
ties; the methodology for their development is explained 1n U.S. EPA (1983a).

    For compounds for which there  1s  sufficient  evidence  of carcinogenicity,
AIS  and  AIC values  are not  derived.   For a discussion  of  risk  assessment
methodology  for  carcinogens   refer to  U.S.   EPA  (1980).   Since cancer 1s  a
process that  1s  not characterized  by  a  threshold,  any exposure contributes
an Increment of risk.   Consequently,  derivation  of  AIS and  AIC values  would
be  Inappropriate.   For carcinogens,  q-|*s have  been  computed based  on  oral
and inhalation data 1f available.
                                      1v

-------
                                   ABSTRACT


    In  order  to  place the  risk  assessment  evaluation  1n  proper  context,
refer  to  the preface  of   this  document.   The  preface outlines  limitations
applicable to all documents of  this  series as  well  as the appropriate Inter-
pretation and use of the quantitative estimates presented.

    Considerable  data  are  available  concerning  the  Inhalation  exposure
effects of  toluene.   U.S.  EPA  (1985)  has  explored a  number of  risk  assess-
ment  strategies  and  has chosen  to  use the CUT  (1980) rat  Inhalation  study
as a  basis  for  their drinking water AADI  since  H  provides  the  most  protec-
tive  estimate.   The  Inhalation  AIS and AIC,  both  104.9 mg/day,  are  based on
the  same  rat  Inhalation study  (CUT,  1980).   It 1s  reasonable  that  the  AIS
and  AIC  should  be  closely aligned  since, as  U.S.  EPA  (1985)  points  out,
cumulative effects following  low level exposures to  toluene are  not  antici-
pated.  A CS  of 7 based on CNS  dysfunction  1n  humans occupatlonally  exposed
to 300 ppm has been calculated.

    Data concerning  the toxlcologlcal  consequences of  oral  toluene  exposure
are  extremely  limited.  One  study was located  In which rats were  adminis-
tered  118,  354  or 590  mg/kg  toluene by gavage, 5  days/week for  27-28  weeks
(Wolf  et  al.,  1956).   All of these  doses  were reported  to  be NOELs.   NOELs
are  generally  not used for   risk  assessment  purposes  1n the  absence  of  a
LOEL; however,  1n this  Instance  the  estimate  agrees with  estimates developed
for  Inhalation  exposure where  data  are more  complete.   Therefore,   an  oral
AIS  of  30 mg/day  (590 mg/kg x  5/7 x 70 kg * an  uncertainty factor   of  100)
1s  suggested  as an  Interim  estimate.   The U.S.  EPA  (1985)  derived  an  oral
AADI  of  20.3  mg/day from  the rat  Inhalation  study by CUT  (1980).   For  the
purposes of  this document, the  ADI  of 20.3  mg/day 1s proposed  for  the  oral
AIC  until  more  appropriate   data  are  available.   This  estimate  should  be
reviewed when more complete data are available.

-------
                               ACKNOWLEDGEMENTS
    The  Initial  draft  of  this  report  was  prepared  by  Syracuse  Research
Corporation under  Contract No.  68-03-3112  for EPA's  Environmental  Criteria
and  Assessment  Office,  Cincinnati,  OH.   Dr. Christopher  DeRosa and  Karen
Blackburn were the Technical Project Monitors  and  Helen Ball  wasithe Project
Officer.  The final documents  1n this  series  were  prepared  for the Office of
Emergency and Remedial Response,  Washington, DC.

    Scientists from  the  following  U.S. EPA offices  provided  review  comments
for this document series:

         Environmental Criteria and Assessment Office, Cincinnati, OH
         Carcinogen Assessment Group
         Office of A1r Quality Planning and Standards
         Office of Solid Waste
         Office of Toxic Substances
         Office of Drinking Water

Editorial review for the document series was provided by:

    Judith Olsen and Erma Durden
    Environmental Criteria and Assessment Office
    Cincinnati, OH

Technical support services for the document series  was provided by:

    Bette Zwayer, Pat Daunt, Karen Mann and Jacky Bohanon
    Environmental Criteria and Assessment Office
    Cincinnati, OH
                                      v1

-------
TABLE OF CONTENTS

1.
2.


3.










4.








5.


ENVIRONMENTAL CHEMISTRY AND FATE 	
ABSORPTION FACTORS IN HUMANS AND EXPERIMENTAL ANIMALS . . . ,
2.1.
2.2.
ORAL 	
INHALATION 	 ,
TOXICITY IN HUMANS AND EXPERIMENTAL ANIMALS 	 ,
3.1.


3.2.


3.3.


3.4.
SUBCHRONIC 	
3.1.1. Oral 	 ,
3.1.2. Inhalation 	 ,
CHRONIC 	
3.2.1. Oral 	
3.2.2. Inhalation 	
TERATOGENICITY AND OTHER REPRODUCTIVE EFFECTS 	
3.3.1. Oral 	
3.3.2. Inhalation 	
TOXICANT INTERACTIONS 	
CARCINOGENICITY 	
4.1.


4.2.


4.3.
4.4.
HUMAN DATA 	
4.1.1. Oral 	
4.1.2. Inhalation 	
BIOASSAYS 	
4.2.1. Oral 	
4.2.2. Inhalation 	
OTHER RELEVANT DATA 	
WEIGHT OF EVIDENCE 	
REGULATORY STANDARDS AND CRITERIA 	
Page
1
3
. . . 3
3
4
, , , 4
. . . 4
4
4
, . . 4
4
. . . 9
. . . 9
10
11
, . . 13
13
. . . 13
. . . 13
13
. . . 13
13
. . . 13
. . . 14
. . . 15

-------
                          TABLE OF CONTENTS  (cont.)

                                                                        Page

 6.  RISK ASSESSMENT	    16

     6.1.   ACCEPTABLE  INTAKE SUBCHRONIC (AIS)  	    16

            6.1.1.   Oral	    16
            6.1.2.   Inhalation	    16

     6.2.   ACCEPTABLE  INTAKE CHRONIC (AIC)	    17

            6.2.1.   Oral	    17
            6.2.2.   Inhalation	    18

     6.3.   CARCINOGENIC POTENCY (q^J	    19

 7.  REFERENCES	    20

APPENDIX: Summary Table for  Toluene	    33

-------
                               LIST OF TABLES

No.                               Title                                Page

3-1     Subchronlc Toxldty of Toluene.	     5

3-2     Effects of Intermittent Subchron1c/Chron1c Vapor Exposures
        to Toluene on Humans	     7

3-3     Interaction of Toluene With Other Chemicals During
        Simultaneous Exposure 	    12
                                     1x

-------
                             LIST OF ABBREVIATIONS





AADI                    Adjusted acceptable dally Intake



ADI                     Acceptable  dally Intake



AIC                     Acceptable  Intake chronic



AIS                     Acceptable  Intake subchronlc



BCF                     Bloconcentratlon factor



CNS                     Central nervous system



CS                      Composite score



DNA                     Deoxyr1bonucle1c add



EEG                     Electroencephalogram



PEL                     Frank-effect level



LOAEL                   Lowest-observed-adverse-effect level



MED                     Minimum effective dose



NOAEL                   No-observed-adverse-effect  level



NOEL                    No-observed-effect level



ppm                     Parts per million



RQ                      Reportable  quantity



RVj                     Dose-rating value



RVe                     Effect-rating value



STEL                    Short-term exposure limit



TLV                     Threshold limit value



TWA                     Time-weighted average

-------
                     1.   ENVIRONMENTAL  CHEMISTRY  AND  FATE



    The relevant physical  and  chemical  properties  and environmental fate  of

toluene (CAS No.  108-88-3)  are  given  below.
    Chemical  class:


    Molecular weight:

    Vapor pressure:


    Water solubility:

    Octanol/water partition
     coefficient:

    Soil mobility:
     (predicted as retardation
      factor  for soil  depth of
      140 cm and organic carbon
      content of 0.087%)

    BCF:
    Half-life 1n air:

    Half-life 1n water:
monocycllc aromatic hydrocarbon
(purgeable aromatic)

92.1

28.1 mm Hg at 25°C
(Mackay et al., 1982)

534.8 mg/8. at 25°C (U.S. EPA, 1982b)
537 (Hansch and Leo, 1981)

1.8 (WHson et al., 1981)
13.2 (1n eel, Angullla japonlca)
(Ogata and Mlyake, 1978)

20 (1n blueglll, Lepomls macrochlrus)
(Berry, 1980)

24.5 (1n crayfish, Orconectes rustlcus)
(Berry, 1980)

1.3 days (Singh et al., 1981)

4.1 hours (Mackay and Yeun, 1983)
    The half-life of toluene (1.3 days)  1n air  1s  based  on  Us  reaction with

OH» radicals.   In the  presence  of  smog,  however,  the half-life of  toluene

may be shorter because of Its reaction with NO  (Van Aalst et  al.,  1980).
                                      -1-

-------
    The values for  the  half-life of toluene  1n  soil  could  not  be located In
the  available  literature.    However,   evaporation   Is  expected  to  be  the
predominant  loss  mechanism from  the  soil surface.   The  half-life  for  soil
evaporation  1s  expected  to  be  longer  than  Its  evaporation half-life  from
water.  In  subsurface  soil,  toluene may  undergo  variable  degrees of  bio-
degradation depending on  the  nature of the soil  (Wilson  et  al.,  1981,  1983;
McNabb et  al.,  1981),  but  a  certain portion  of the undegraded  toluene  may
percolate through soil Into groundwater (Wilson et al.,  1981).
                                      -2-

-------
           2.  ABSORPTION FACTORS  IN HUMANS AND EXPERIMENTAL MAMMALS
2.1.   ORAL
    Urinary excretion accounted for 74-80% and pulmonary  exhalation  account-
ed  for  an additional 18-19%  of  the  toluene  administered orally  to  rabbits
(El Masry et al.,  1956;  Smith  et al.,  1954),  Indicating  that   toluene  1s
almost  completely  absorbed   from the  gastrointestinal  tract  In  rabbits.
Maximum absorption of toluene from the  gastrointestinal tract  of  rats  occurs
within 2  hours  of Intubation,  as  evidenced  by blood-toluene  levels  (Pyykko
et al., 1977).
2.2.   INHALATION
    Dogs  absorbed  85-94%  of  the  toluene  that entered their lungs  (Egle  and
Gochberg,  1976).   Mice  retained -60%  of   the  Inspired  toluene  after  a
I0-m1nute exposure (Bergman,  1979).
    In humans,  the arterial  concentration  of toluene was  Increased  quickly
as  compared  with both  the concentration  of  toluene 1n the alveolar  air  and
Us concentration  1n  the Inspired  air  (Astrand et  al.,  1972;  Astrand,  1975).
Although  the  human absorption rate during the first  hour  of  toluene Inhala-
tion  was  57%, Us absorption  rate leveled off at  37% of the  Inspired  dose
2-4  hours  after  the  start   of   exposure  (Nomlyama  and  Nomlyama,  1974).
Exercise  affects  the absorption  rate  of  toluene  1n humans  (Astrand  et  al.,
1972; Carlsson, 1982).
                                      -3-

-------
                3.  TOXICITY  IN  HUMANS  AND  EXPERIMENTAL  ANIMALS
3.1.   SUBCHRONIC
3.1.1.   Oral.   In  the  only animal  study  on  subchronlc  oral  exposure  to
toluene, 30 female Wlstar rats  received  118,  354  or  590 mg/kg/day of toluene
1n  olive  oil,  5 days/week for  27-28  weeks (Wolf  et a!.,  1956).   There were
20  control rats.  After  clinical  and gross  Inspection  as  well  as  hlstologl-
cal evaluation  of  the kidneys  and liver, no  effects  were reported  for  any
dose level (Table 3-1}.
3.1.2.   Inhalation.    Subchronlc   Inhalation  studies   1n  animals  Indicate
that  female  rats are  more  sensitive to  toluene  than  male rats  (Ungvary  et
a!.,  1980)  and  that  changes In  the  liver,  blood and  body  weight  are  the
first effects  seen  after subchronlc  Inhalation  of  toluene (see  Table 3-1)
(Ungvary  et  al., 1980;  American   Petroleum  Institute,   1980;  Pryor  et al.,
1983a,b).  Male and  female  CFY rats  were exposed to  1000 mg/m3  (265 ppm)
toluene  for  6  hours/day, 5  days/week for 6  months. (Ungvary et al.,  1980).
No  effect  was  seen  1n  the  males.   However,  the females  had an  Increased
level of  cytochrome  P-450,  decreased  body weight and  an  Increased  ratio  of
liver weight  to total  body  weight.   At  the  next exposure  level,  3500  mg/m3
(928 ppm), male  rats were exposed  for  8  hours/day,  5  days/week for 6 months.
Effects  were  similar   to  those  seen  1n  the  females at the lower  dose.   No
females were tested at the higher  dose level.
3.2.   CHRONIC
3.2.1.   Oral.   Pertinent  data  regarding  chronic oral  exposure  to  toluene
could not be located  1n the  available literature.
3.2.2.   Inhalation.    Male and  female Fischer  rats were exposed  to  30,  100
and 300  ppm of  toluene  for  6  hours/day,  5  days/week  for 24 months  (CUT,
1980).   At  a  dose  of  30  ppm,   there  was  no  difference  1n  hematology,
                                      -4-

-------
                                                                            TABLE  3-1

                                                                 Subchronlc Toxlclty of Toluene
Route
Oral*
Inhalation
Dose/Exposure
controls
118 mg/kg/day
354 mg/kg/day
590 mg/kg/day
265 ppm
Duration of Exposure
5 days/week for 27.6
weeks (138 doses)
6 hours/day. 5 days/
week, 3 months
Species/Sex
Ulstar rats/F
CFt rats/M&F
Number
20
10
10
10
NR
Effect
No effect after gross and clinical
Inspection and htstologlcal evalua-
tion of kidneys and liver at any
dose level tested.
Cytochrome P-450 Increased; de-
creased body weight and Increased
Reference
Wolf et al..
1956
Ungvary
et al.. 1980
         Inhalation     928 ppm
in
i
         Inhalation
         Inhalation
   0 ppm
 100 ppm
1500 ppm
controls
 900 ppm
1400 ppm
         Inhalation
107 ppm
                                          6  hours/day. 5 days/
                                          week, 6 months
                  8 hours/day.  5  days/     CFY rats/N
                  week.  6 months
                                                         liver weight  In  females.

                                                         Cytochrome P-4SO Increased;  In-
                                                         creased  liver  to body weight ratio;
                                                         decreased body weight In  females.

                                               NR         Increased cytochrome P-450;  In-
                                                         creased  dilation of rough endo-
                                                         plasmlc  retlculum and autophagous
                                                         bodies In hepatocytes; decreased
                                                         glycogen and  total body weight;
                                                         Increased relative liver  weight.
6 hours/day.  5 days/
week. 26 weeks
14 hours/day.  7 days/
week, 14 weeks
Sprague-Dawley
rats/H&F
F-344 rats/H
15/sex/
exposure
level
 11-12
continuous for
90 days
rats/NR
guinea ptgs/NR
dogs/NR
monkeys/NR
None
900 ppm: Initial decreased body
weight; reduction In motor neuron
activity 2-8 weeks.
1400 ppm: Sustained decreased body
weight; reduction In motor neuron
activity 2-8 weeks; loss of tone-
Intensity discrimination hearing
ability; decreased learning behavior.
   NR        Two rats died, but other effects not
   NR        observed.  The parameters evaluated
   NR        were hematology. body weight and
   NR        histology of lung, liver, kidney,
             heart and spleen.
                                                                        Ungvary
                                                                        et  al.,  1980
American
Petroleum
Institute.
1980

Pryor et al.
1983a,b
                                        Jenkins
                                        et al., 1970
         'Administered by gavage In olive  oil

         NR =  Not  reported

-------
urlnalysls or clinical chemistry between  the  treated  and  control  groups.   At
the 100 and  300  ppm dose levels, the only reported effect  was  a  decrease In
the hematocrH of female rats.
    Because  of  Us  widespread  use  In the workplace  and because  of  toluene
abuse (glue  sniffing),  the  effects  of chronic exposure  to  toluene have been
studied extensively  In  humans.   Some of  the occupational  exposure  studies
are summarized In Table  3-2.   One of the more striking  features  of the data
on the  subchronlc  and chronic  effects  of toluene exposure  on  humans  1s  the
failure  of  Increased  periods  of  Intermittent  exposures  to  cause  clearly
Increasing  severe  effects.    Although  the utility  of the  available  studies
for estimating  firm dose-response  relationships  1s  somewhat limited  by  the
failure  to  define  precise  levels   and  duration  of   exposure,  problems  of
sample  size, the  potential  role  of  other   toxic  agents  1n  eliciting  the
reported  effects,   and  some  apparent  Inconsistencies  among  the  available
studies,  the  weight  of evidence suggests that the  types  of effects seen  and
the levels at which  effects are seen are relatively Independent of the dura-
tion  of  exposure.   For  mean  exposure  levels  >200 ppm, all  of  the available
studies  except   that  of Suhr  (1975)  report some   evidence of  neurologic
effects  (see Table  3-2);  Interpretation of  the  significance  of  the  large
scale,  Suhr  (1975)   study  1s  confounded by the  factors  outlined  1n  the
footnote  to Table 3-2.
    For exposures  of >200 ppm,  the reports   of  headache,  nausea  and  concen-
tration-related  Impairment  of  coordination  (Wilson,  1943) are  consistent
with  the  relatively  well-documented  CNS  effects  of  single  exposures  to
toluene.   This   1s   not  unexpected  since blood  levels  of  toluene  decline
rapidly   following  cessation   of  Inhalation   exposure  (toluene   1s  rapidly
absorbed  and eliminated)  (SRC,  1981).   For  single   experimental  exposures
                                      -6-

-------
                                                 TABLE 3-2

              Effects of Intermittent Subchronlc/Chronlc Vapor Exposures to Toluene on Humans
             Exposure
                    Effects
   Reference
Dally exposure to commercial  toluene
for 1-3 weeks:
  500-1500 ppm (-10% of the patients)
  200-500 ppm (-30% of the patients)
  50-200 ppm (-60% of the patients)
200-800 ppm for "many" years
250 ppm for "diverse" years
125 ppm
200-400 ppm pure toluene (<0.3%)
100 of a total of 1000 workers showed symptoms
severe enough to cause them to present them-
selves for hospital examination

Nausea, headache, dizziness, anorexia, palpita-
tion, extreme weakness; pronounced loss of
coordination and Impaired reaction

Headache, nausea, bad taste In mouth, anorexia,
lassitude, slight Impairment of coordination
and reaction time, transient memory loss

Headache, lassitude and loss of appetite; mild
symptoms that were attributed to psychogenlc
and other factors rather than exposure

Signs of "nervous hyperexcltablllty" In 6/11
paint and pharmaceutical Industry workers

Stupor, nervousness and Insomnia In one V-belt
manufacturing worker

No CNS effects In 17 V-belt manufacturing
workers

No evidence of adverse neurological effects
(subjective complaints Indicative of CNS
depression, abnormal reflex reactions. Impaired
muscular coordination) In 100 rotogravure
workers*; responses compared with an unexpected
control group of equal size.
Wilson, 1943
Wilson, 1943
Wilson. 1943
Wilson. 1943
Parmegglanl and
Sassl, 1954

CapelUnl and
Alesslo, 1971

CapelUnl and
Alesslo, 1971

Suhr, 1975

-------
                                                 TABLE 3-2 (cont.)
                 Exposure
                    Effects
                                                                                                   Reference
    300 ppm for 18 years
    430 ppm for 12 years
    30 ppm toluene and 2-7 ppm other
    organic solvents for 1-40 years
CXI
    60-100 ppm toluene with 20-50 ppm
    gasoline In a "few" working places
    >250 ppm and trlchloroethylene
    (concentration not stated)
Subjective memory, thinking and activity dis-
turbances In 21% of the 300 ppm group (printers)
and 40?t of the 430 ppm group (printers'  helpers);
110 workers tested (no control subjects);
Rorschach test results consistent with the
findings In 835t of the cases

Impaired behavioral responses In 100 car
painters relative to 101 age-matched nonexposed
controls; a battery of behavioral tests Indi-
cated that Impairments In visual and verbal
Intelligence and In memory as well as a reduc-
tion In emotional reactivity (Rorschach test)
were the predominant effects of exposure

Evidence of peripheral neuropathy (e.g., ab-
normal tendon reflexes and grasping power) In up
to 14/38 female shoemakers; responses compared
with 16 unexposed controls; 19/38 exposed women
(3 of 16 controls) complained of dysmenorrhea

Changes In EEG response to photic stimulation
Hunchlnger,
1963
Hannlnen
et al.. 1976
Matsushita
et al.. 1975
Rouskova, 1975
    *Th1s  conclusion Is  considered  equivocal  (SRC,  1981) because  the control  group was  undefined,  because
     blood toluene levels may have significantly declined at the time of reflex reaction and muscular coordina-
     tion  testing,   and  because muscular  coordination  was  evaluated  with an  apparently  unvalldated  device
     (sphallograph).

-------
that approximated  a  normal working  day  (7-8 hours) and  Involved  a combined
total of five subjects on  multiple  exposure/recovery  schedules,  1t was found
that  subjective  complaints  such  as  fatigue,  muscular weakness,  confusion,
Impaired coordination,  slight exhilaration,  enlarged  pupils  and  accommoda-
tion disturbances were first  observed  at  levels  of  200 ppm (von Oettlngen et
al., 1942a,b; Carpenter  et al.,  1944).  These effects  Increased  1n severity
with  Increases   1n  toluene  concentrations  until  at  800  ppm the  subjects
experienced  changes  such  as  severe  fatigue, pronounced  nausea, mental  con-
fusion, headaches, considerable  1ncoord1nat1on and  staggering gait, strongly
Impaired accommodation  to light and  scotomata  (areas of  depressed vision).
Carpenter  et  al. (1944)  also reported that  toluene  causes mild  throat  and
eye  Irritation  at 200 ppm and  lacrlmatlon  at  400 ppm.   Short-term experi-
mental  exposures  to  toluene  at  concentrations  >100  ppm  have also elicited
Increases  1n  reaction time   (200 ppm x  3 hours)  (Ogata  et  al.,   1979)  and
reduction  1n  perceptual  speed  (300  ppm  x  20  minutes)  (Gamberale  and
Hultengren, 1972).
    Toluene  abuse,  1n  several  cases for  as long  as 10-14 years,  caused
severe  effects  Including  ataxla,  tremors,  1ncoord1nat1on, emotional  Insta-
bility,  nystagmus,  a  positive  Bablnskl   response, psychoses and  decreased
cerebellar   functioning   (Knox and  Nelson,  1966;  Satran   and Oodson,  1963;
Kelly,  1975;  Boor  and Hurtig, 1977;  Welsenberger,  1977;  Sasa et  al.,  1978;
Keane, 1978; Tarsh, 1979; Malm and Lylng-Tunell,  1980).
3.3.   TERATOGENICITY AND OTHER REPRODUCTIVE EFFECTS
3.3.1.   Oral.   In  an abstract,  Nawrot  and Staples  (1979)  reported  that
there was  a  significant  Increase 1n fetal mortality when  pregnant CD-I  mice
were  treated  by  gavage  with  0.3,   0.5  and  1.0  ma/kg/day  (0.26,  0.43  and
0.87 g/kg/day)  of  toluene  1n cottonseed  oil on  days 6-15  of  gestation.
                                      -9-

-------
Increased  (statistically  significant)  fetal  mortality was  observed at  all
dose  levels  and fetal  weights were  decreased when  the  pregnant mice  were
exposed  to  0.43  and 0.87 g/kg/day  toluene  on days 6-15 of  gestation.   Only
the  highest  dose  level  (0.87  g/kg/day) caused  an  Increased  Incidence  of
cleft palate In  the offspring.  Maternal toxldty was not  seen under  any of
the  conditions  described  above.   Because these  results  appeared  only  In an
abstract without statistical analysis they must be considered preliminary.
3.3.2.   Inhalation.  Pregnant  ICR  mice  were  exposed  to  toluene  vapor  at  a
level  of 100  ppm   (377  mg/m3) and  1000 ppm (3770 mg/m3)  for   6  hours/day
on  days 1-17  of  gestation  (Shlgeta  et  al.,  1982).   There were  18  mice
exposed  to  the low dose, 14  mice exposed  to the high dose  and 15  controls.
Approximately  two-thirds of  each  group of animals were sacrificed  on  day 18
of  gestation.   The fetuses  were  examined  for extra ribs,  fused  ribs,  cleft
vertebrae,  cleft sternum,  cran1osch1s1s  and  polydactyly, and  1n  the absence
of  observed effects, the authors  concluded  that  toluene was not  fetotoxlc or
teratogenlc.   Although there  were more resorbed  fetuses  1n  treated  mice, the
Increased resorptlon was  neither  statistically significant  nor  dose-related.
No  abnormalities were  detected up  to  14 weeks after  birth  1n  the  offspring
of  toluene-exposed mothers  (Shlgeta  et  al., 1982).  CFLP  mice  (Hudak  and
Ungvary, 1978) were exposed   to  toluene vapor  at  a  level  of  500  and  1500
mg/m3  continuously on  days  6-13  of gestation.   All  of  the mice exposed to
1500  mg/m3  died  within  24   hours  of  exposure.    Decreased  fetal  weight,
Indicating  fetotoxldty,  occurred   1n  the  offspring of   mice  treated  at
500  mg/m3.
     The  offspring  of Charles  River  rats exposed  to  toluene vapor at concen-
trations  of  100  and  400  ppm (377  and  1500 mg/m3),  respectively,  for  6
hours/day on  days  6-15  of gestation (Litton  Blonetlcs,  Inc.,  1978a) did not
                                     -10-

-------
have an  Increased  Incidence of  visceral  or  skeletal  'abnormalities as.  com-
pared with  a  control  group.   No maternal  or  fetal  toxldty was  reported
(Litton   B1onet1cs,  Inc.,  1978a).   A  group  of 20  CFY  pregnant  rats  were
exposed   to  toluene  vapor  at  a  concentration  of  1000 mg/m3  (ppm)  for  24
hours/day on  days  7-14 of gestation  (Tatral  et a!.,  1980).   A group of  22
pregnant CFY  rats  constituted  the control group.  Although  toluene  exposure
at  this  level did  not significantly  alter  maternal  or  fetal mortality  or
body weights,  retarded  skeletal  growth as judged by  Inspection of  alizarine
stained  fetuses occurred at a  statistically significant level  1n  the  toluene
exposure group.  In another experiment, one group of  10 CFY  rats  was  exposed
to  toluene  vapors  at a concentration  of  1000 mg/m3 for 8 hours/day on  days
1-21 of  gestation;  another group  of  9 rats was  exposed  to  1500 mg/m3  con-
tinuously on days 1-8 of gestation;  and a third group of  26  rats  was  exposed
to  1500  mg/m3  continuously on  days  9-14  of gestation.   Although  there  were
no  visceral  or external  malformations because  of  toluene  exposure  at  the
levels  tested,  retarded  skeletal development  (poorly ossified  sternebrae,
split vertebral centra and shortened free ribs)  or  skeletal  anomalies  (extra
ribs and  fused sternebrae)  occurred  at  all  three  levels tested  (Hudak  and
Ungvary, 1978).
3.4.   TOXICANT INTERACTIONS
    The   Interactions  of   toluene with   benzene,  xylene,  hexane,  ethanol,
acetylsallcyHc add, tMchloroethylene and  perchloroethylene  are summarized
1n Table 3-3.
                                     -11-

-------
                                                                            1ABLE 3-3
                                             Interaction of Toluene with Other Chemicals During Simultaneous Exposure
i
IS)
Route of
Toluene
Exposure
NR
Inhalation
Inhalation
Inhalation
Inhalation
Intraperl-
toneal
Oral
Intrapert-
toneal
Dose of
Toluene
Exposure
NR
100 ppm.
2 hours
1060 ppm.
6 hours/day,
5 days/week,
4 weeks
80 ppm, 3 hours
1000. 2000 and
3600 mg/m».
continuously on
days 10-13 of
pregnancy
430 mg/kg
NR
0.1 mg/kg
0.2 mg/kg
Other Route of Dose of
Chemical Exposure Other Chemical Species
benzene NR 24.2-97.7 mg/kg rats
390.6 mg/kg
benzene Inhalation 25 ppm, 2 hours humans
ethanol oral NR rats
ethanol oral 1.5 ml/kg humans
acetylsall- oral 250 mg (on CFY rats
cyllc acid day 12)
(aspirin)
trlchloro- Intraperl- 730 mg/kg NR
ethylene toneal
perchloro- oral NR rats
ethylene
m-xylene Intraperl- 0.1 mg/kg male rats
toneal 0.2 mg/kg
Effect
Dose-dependent Inhibition
of benzene metabolism by
toluene at higher dose
levels
No effect on metabolism of
toluene or benzene
Additive effect on myo-
cardlal Increased vascular
resistance
Inhibited toluene metabo-
lism (however, regular
alcohol consumption lowered
blood toluene levels In
workers occupatlonally
exposed to toluene)
Toluene potentiated the
effect of aspirin on
mothers (decreased weight
gain and Increased liver
weight) and on fetuses
(Increased skeletal and
renal anomalies and In-
creased Incidence of club-
foot, cleft palate and
polydactyly).
Competitive Inhibition
Toluene toxlclty poten-
tiated.
No effect on total urinary
excretion, but the rate was
slightly depressed.
Reference
Sato and
Nakajlma, 1979
Sato and
Nakajlma. 1979
Horval and
Ungvary, 1979
Ualdron
et al., 1983
Ungvary
et al., 1983
Ikeda, 1974
Smyth et al.,
1969
Ogata and
Fujll. 1979
         NR =  Not reported

-------
                             4.  CARCINOGENICITY
4.1.   HUMAN DATA
4.1.1.   Oral.    Pertinent  data  regarding  the  human  cardnogenldty  of
toluene  following  oral  exposure  could  not  be  located  In  the available
literature.
4.1.2.   Inhalation.   Pertinent data regarding  the  human  cardnogenldty of
toluene following Inhalation exposure  could  not be  located 1n the available
literature.
4.2.   BIOASSAYS
4.2.1.   Oral.   Pertinent  data  regarding the cardnogenldty  of  toluene to
experimental animals  following oral  exposure  could  not  be  located  1n  the
available literature.
4.2.2.   Inhalation.   The  chronic  bloassay (2  years)  of  toluene In  Fischer
344 rats of both sexes  showed  no carcinogenic effects  (CUT,  1980).   Approx-
imately 90  rats/sex/dose were  exposed  to 30,  100  or 350  ppm (113,  377 or
1130  mg/m3,  respectively)  toluene  for  6  hours/day,  5 days/week.  Although
females exposed  to 100  and 300 ppm  (370 or 1130  mg/m3)  had  significantly
reduced  hematocrlt  levels, no dose-response  effect  was  present.    After
hematologlcal and  hlstopathologlcal  evaluation, no  other  difference  between
treated and  control  groups  was observed.  However,  there  was a high  spon-
taneous Incidence (16%) of mononuclear cell leukemia 1n the control group.
4.3.   OTHER RELEVANT DATA
    Toluene has been shown  not  to  be  mutagenlc  1n the presence or absence of
rat liver  homogenate  1n Salmonella typhlmuMum strains TA98,  TA100,  TA1535,
TA1537  and TA1538  (Litton  Blonetlcs,  Inc.,  1978b;  Mortelmans  and  R1cdo,
1980; Nestmann et al.,  1980; Snow  et  al.,  1981; Bos et al.,  1981),  1n Esche-
rlchla  coll  strain WP2  (Mortelmans  and  R1cdo,  1980)  and  In  Saccharomyces
                                     -13-

-------
cerevlslae strains D4 and D7  (Mortelmans  and  Rlccio,  1980).   Toluene did not

damage DNA  1n  DNA repair deficient  strains  of E_. coll  (Pluck  et  al.,  1976)

and S>. typhlmurium (Mortelmans and R1cdo, 1980).

    Preliminary  data  Indicate  that  toluene may  decrease fetal weight  gain

and Increase fetal mortality  and the Incidence  of cleft palate 1n the  fetus

when CD-I mice are exposed  orally  on  days 6-15 of gestation at doses of  260,

430 and  870 mg/kg/day  (Nawrot  and Staples,  1979).   Maternal  Inhalation  of

toluene  1n  mice  and  rats  during pregnancy  did not  cause  a  statistically

significant  effect,   although  skeletal   anomalies   and   resorptlon   were

Increased 1n some  experiments  (Tatral  et al., 1980;  Litton  Blonetlcs,  Inc.,

1978a; Shlgeta et al., 1982).
      j
4.4.   WEIGHT OF EVIDENCE

    The rate and Incidence  of  tumor  formation  1n rats exposed to toluene for

2  years  were  not  significantly  different from the  rate  and  Incidence  of

tumor  formation  In control  rats  (CUT,  1980).   Because  human exposure  to

toluene  1n   the  workplace  occurs  often  and  because toluene  1s  an  abused

substance, there are many reports  of  human  exposure  1n the  literature.   None

of  the reports  associates  toluene  exposure with  Increased  rate or Incidence

of  cancer.   IARC has  not evaluated  the risk to  humans  associated with  oral

or  Inhalation  exposure  to  toluene.   Applying the criteria  proposed by  the

Carcinogen  Assessment  Group   of  the   U.S.  EPA  (Federal  Register,  1984),

toluene Is most appropriately  designated a Group  D -  Not Classified chemical.
                                     -14-

-------
                     5.   REGULATORY STANDARDS AND CRITERIA







    ACGIH (1983) currently recommends a TWA-TLV of  100  ppm and  a STEL of 150



ppm.  NIOSH  (1973)  recommends  a TWA of 100  ppm,  with a celling of  200  ppm.



OSHA currently  limits  occupational  exposure to toluene to a TWA  concentra-



tion of  200 ppm, with  a celling of  300  ppm  (Code of  Federal  Regulations,



1981).
                                     -15-

-------
                             6.   RISK ASSESSMENT
6.1.   ACCEPTABLE INTAKE SUBCHRONIC (AIS)
6.1.1.   Oral.   In  the  only study available  on  oral subchronlc  exposure  to
toluene (Wolf et  al.,  1956),  all  the dose  levels  Including  the  highest  dose
level  of  590  mg/kg/day,  5 days/week  for  27.6   weeks  were  NOELs.   In  an
abstract,  Nawrot  and  Staples  (1979) reported  Increased  embryo death  1n  all
treatment  groups  when  pregnant  mice received  260, 430 and  870  mg/kg/day  of
toluene by  gavage  on   days  6-15   of  gestation.    Although   the  experimental
design and results  were sparsely  reported In  this abstract,  the  data  cannot
be discounted.
    An AIS for  oral  exposure  can  be calculated using  the  highest freestand-
ing NOEL  (590 mg/kg)  from the Wolf et al.  (1956)  study.   Multiplying  by  5/7
to  estimate  continuous  exposure,  by 70  (the  assumed human  body  weight)  and
dividing  by  an   uncertainty factor  of  1000  (10  for Interspecles  extrapola-
tion,  10  for  Intraspecies differences   1n  sensitivity  and  10  because  of
concern for  potential  fetotoxlc  effects)  results  1n an estimated AIS of  30
mg/day.
6.1.2.   Inhalation.  Animal  studies  Indicate that  toluene  is fetotoxlc  In
mice  and   rats   (Hudak  and Ungvary,  1978;   Tatral  et  al.,  1980;   Litton
Bionetics, Inc.,  1978b; Shigeta et al.,  1982).  However,  the NOAEL  for feto-
toxlclty  in mice  Is  833.33 mg/kg/day (Hudak and Ungvary,  1978),  obtained  by
multiplying  the  continuous  exposure   level   of   500   mg/m3  by  the  mouse
inhalation rate  of 0.05  mVday   and  dividing by  the  estimated  body  weight
of a mouse (0.03  kg).   In  rats, the  retarded  skeletal  development was  judged
to  be  a  PEL  and  occurred  at  a dose of  247.6 mg/kg/day  (Hudak  and Ungvary,
1978), obtained  by multiplying  the intermittent  exposure  level  by  1/3  (8
hours/day) and  the rat Inhalation rate  (0.26 mVday) and  dividing  by  the
                                     -16-

-------
estimated body weight  of  a rat  (0.35  kg).   Following the same  dose  conver-
sion methods, a dose of 278.6 mg/kg/day was  reported  to  be a  NOEL  1n  the rat
(Litton B1onet1cs,  Inc.,  1978a).
    Other subchronlc Inhalation  studies from which a NOAEL or  NOEL could be
derived  were not  located,  Ungvary  et  al.   (1980)   and  American  Petroleum
Institute (1980) and  Pryor et al.  (1983a,b), provide Insufficient  Informa-
tion  on  results  and  experimental design  for adequate  evaluation and  risk
assessment.   However,  the chronic Inhalation  data  from the CUT (1980)  study
can  be  used.  The  concentration of toluene 1n air,  1130 mg/m3,  1s  multi-
plied by  6/24 and  5/7  to correct  for an exposure  of  6  hours/day,  5  days/
week, and  the result  1s  multiplied by 0.26 m3/day  (an  assumed respiratory
volume 1n rats) and divided  by 0.35  kg (the  assumed body weight of rats).  A
dose  of   149.90  mg/kg/day  1s  calculated.    Application  of  an  uncertainty
factor of 100 (10  to afford  greater  protection  for sensitive  Individuals and
10  for  Interspedes extrapolation)  and multiplying  by   70  kg, the  assumed
average  body weight of humans,  results 1n  an AIS of 104.9 mg/day.   This Is
the  same value estimated for chronic exposure.   Since  toluene  1s  rapidly
metabolized  and  cleared,  cumulative  effects  would  not  be  anticipated.
Therefore,  1t  1s   not  unreasonable  to estimate  the  same value  for both AIS
and AIC exposures.
6.2.   ACCEPTABLE INTAKE  CHRONIC  (AIC)
6.2.1.   Oral.  It  1s  suggested  that  the  U.S. EPA (1985)  ADI  of 20.3 mg/day
be  adopted  as an  Interim oral  AIC.   This   value  1s  based on  an  Inhalation
NOAEL  1n rats of  1130 mg/m3  (CUT,  1980).   Since the U.S. EPA (1985)  based
an  oral  ADI  on  Inhalation data,  a route-to-route extrapolation was required.
                                     -17-

-------
This  was  accomplished by expanding  the exposure  (1130  mg/m3)  from 6 hours/
day,  5  days/week  to continuous  exposure,  and  multiplying  by  20 m3  (an
assumed  dally  respiratory   volume  for  humans)  and by  0.5  to  reflect  an
assumed 50%  absorption  factor.   Application of  an  uncertainty  factor of 100
(10  to afford  greater protection  for  sensitive individuals and 10 for Inter-
species extrapolation) results  1n an  ADI  of 20.3 mg/day for oral exposure to
toluene.   This value should  be reviewed  when chronic  oral data  are avail-
able.  For corroborative  purposes,  U.S.  EPA (1985) also projected ADIs based
upon  human Inhalation data  (Hannlnen  et al.,  1976; Seppalalnen et al., 1978)
(projected ADI 41  mg/day);  as  well  as  the TLV  (projected  ADI  135 mg/day).
They  also  cite the  subchronic  oral  NOAEL  of  590 mg/kg in  the  rat (Wolf et
al.,  1956) as  supporting data.
6.2.2.   Inhalation.   Considerable  Information  is  available  regarding  the
CNS  effects  on humans of chronic  inhalation  exposure  to  toluene  (see Table
3-1).  None  of the human studies taken  individually are suitable for use in
human  risk  assessment  because  they  involve  a  relatively  small   number  of
subjects,  Inadequately   document  exposure  levels  or  durations,  or do  not
consider  the  potential  role  of concomitant   exposure  to  other  toxicants.
Collectively,  however,   the human  studies provide  a  relatively  consistent
pattern of dose-response relationships for  CNS effects.
    An AIC for  Inhalation can  be  calculated from the chronic (106 week) data
1n  rats  (CUT, 1980).  The  calculations  are  based on the  rat  NOAEL of 1130
mg/m3,  and  are  identical  to  those   in  Section 6.1.2.   An  AIC of  104.9  is
calculated.
    An RQ  for  toluene was  derived  by U.S. EPA  (1983b)  based  on the accumu-
lated data in  humans  in  the workplace summarized 1n Section 3.2.2.  Although
none  of these  studies is  by Itself  suitable for derivation of  an RQ, collec-
tively, they consitute  a considerable  body of data on  humans  and provide  a

                                     -18-

-------
fairly consistent pattern of dose-response relationships.  Although  the  CUT
(1980) chronic  Inhalation  experiment  defined an effect  at 300 ppm  In  rats,
the  uncertainty  Involved  1n  extrapolating  from an  experimental  animal  to
humans makes selection of  the  human data a more prudent  choice for  calcula-
tion of a CS.
    Consideration of the  Intermittent  subchronlc/chronic  Inhalation  exposure
data  and  the   supporting  acute exposure  data leads  to  the  conclusion  that
exposure periods of  <8 hours  to  toluene  concentrations  <100 ppm may  result
1n  mild  subjective  symptoms  (fatigue of  headache),  but  are  not likely  to
Induce observable effects.  Concentrations >100  ppm may  cause  Impaired  reac-
tion  time,  and concentrations  of >300  ppm would be expected to  cause  gross
signs of 1ncoord1nat1on.   Based  on  all of the available  data, 300 ppm  (1130
mg/m3)  can  be  regarded  as  an unequivocal  effect  level  1n humans.   Since
this  effect level  1s applicable to Intermittent occupational exposures  that
are assumed to occur 5 days/week, an MED  can be calculated  by expanding the
exposure from  5 to  7  days/week,  and  assuming  that a  human breathes 10  m3
of air/workday with  an absorption efficiency  of  50% for  toluene  (SRC,  1981).
This  calculation gives an  MED  of 57.6 mg/kg/day, or 4036  mg/day  for a  70  kg
man.  The  RV   associated  with  a human  MED  of  4036  mg/day  1s  1, since log
MED  1s  >3.   An appropriate RV   reflecting the  (reversible) CNS  dysfunction
1s 7.  The CS would therefore be 7,  which corresponds  to  an RQ  of  1000.
6.3.   CARCINOGENIC POTENCY (q^)
    There are  no data pertaining to  the cardnogenldty  of toluene by  oral
exposure to either humans  or animals.  An  Inhalation  bloassay  1n  rats  (CUT,
1980)  yielded  decidedly  negative  results.   Quantitative carcinogenic  risk
assessment 1s   therefore not appropriate.
                                     -19-

-------
                                7.  REFERENCES

ACGIH  (American  Conference  of  Governmental  Industrial  Hyg1en1sts).   1983.
Threshold  Limit  Values  for  Chemical  Substances and  Physical  Agents  1n  the
Workroom  Environment  with Intended Changes  for 1983-1984.  Cincinnati,  OH.
p. 33.

American  Petroleum Institute.  1980.  A  26-Week  Inhalation  Toxlclty  Study of
Toluene 1n  the Rat.   Project No.  78-7234 conducted by Blodynamlcs,  Inc.  for
American Petroleum Institute, Washington, DC.   (CHed  1n  U.S.  EPA,  1984}

Astrand,  I.   1975.   Uptake of solvents  1n  the  blood  and tissues of man.   A
review.   Scand.  J.  Work,  Environ.  Health.   1(4):  199-218.   (CHed In  U.S.
EPA, 1984)

Astrand,  I., H. Ehrner-Samuel, A. Kllbom and  P.  Ovrum.   1972.   Toluene expo-
sure.   I.  Concentration  1n  alveolar  air  and  blood  at  rest  and  during
exercise.  Work Environ. Health.   72(3):  119-130.  (CHed  1n U.S.  EPA,  1984)

Bergman,  K.   1979.   Whole-body  autoradlography and allied  tracer  techniques
1n distribution and elimination studies  of  some  organic solvents.   Scand.  J.
Work Environ. Health.   5: 263.  (CHed 1n U.S.  EPA,  1984)

Berry, W.O.  1980.  A comparative study  of  the  uptake of  toluene  by  blueglll
sunflsh,  Lepomls  macrochlrus. and  crayfish,  Oronectls  rustlcus.   Environ.
Pollut. Ser. A.  21:  109-119.
                                     -20-

-------
Boor,  3.W. and H.I. Hurtlg.  1977.  Persistent cerebellar ataxla after expo-



sure to toluene.   Ann.  Neurol.   2(5):  440-442.   (CHed  In U.S. EPA, 1984)







Bos, R.P.,  R.M.E.  Brouns, R.  Van Doom, J.L.6.  Theuws  and P.T. Henderson.



1981.    Non-mutagen1c1ty   of  toluene,  o-,  m- and  o-xylene,  o-methylbenzyl



alcohol and  o-methylbenzyl  sulfate  In the Ames  assay.   Mutat.  Res.   88(3):



273-279.  (Cited  1n U.S.  EPA,  1984)







Carlsson,  A.  1982.  Exposure  to  toluene.  Uptake,  distribution and elimina-



tion 1n man.  Scand. J. Work,  Environ. Health.   8(1):  43-55.  (Cited  In U.S.



EPA, 1984)







CapelUnl, A. and  Alesslo L.   1971.   The urinary excretion of hlppurlc add



In workers  exposed  to  toluene.   Med.  Lavoro.   62:  196-201.  (Ita.)   (CHed



1n U.S. EPA, 1983b)







Carpenter, C.P.,  C.B. Shaffer, C.S. Well and H.F. Smyth, Jr.  1944.   Studies



on the  Inhalation of 1,3-butad1ene; with a comparison  of Us narcotic effect



with benzol,  toluol,  and styrene, and a note  on the elimination of  styrene



by the human.  J. Ind.  Hyg. Toxlcol.   26: 69-78.   (CHed  In  U.S.  EPA,  1983b)







CUT  (Chemical   Industry   Institute  of  Toxicology).   1980.  A  twenty-four



month  Inhalation toxicology study In  F1scher-344  rats  exposed to atmospheric



toluene.  Executive  Summary  and Data Tables.   October  15,  1980.  (CHed  1n



U.S. EPA,  1984)







Code of Federal  Regulations.   1981.   OSHA Safety and Health Standards.   (29



CFR 1910.1000)





                                     -21-

-------
Egle,  J.L.  and  8.J.  Gochberg.   1976.   Respiratory  retention  of  Inhaled
toluene  and  benzene  In  the  dog.    J.  Toxlcol.  Environ.  Health.   1(3):
531-538.   (Cited  1n U.S.  EPA, 1984)

El Masry,  A.M.,  J.N. Smith  and  R.T.  Williams.   1956.   Studies 1n detoxifica-
tion.   The metabolism of  alkylbenzenes,  n-propylbenzene and n-butylbenzene
with  further  observations  on ethylbenzene.   Blochem. J.  64:  50-56.   (CHed
1n U.S. EPA, 1984)

Federal  Register.  1984.   Environmental  Protection  Agency  proposed  guide-
lines for carcinogenic risk assessment.  49  FR 46294-46299.

Fluck,  E.R.,  L.A.  Polrler   and  H.W.  Reullus.   1976.  Evaluation  of  a  DNA
polymerase-defldent mutant  of  E..  coll for  the rapid detection  of  carcino-
gens.  Chem. B1ol. Interact.  15: 219.  (CHed 1n U.S. EPA,  1984)

Gamberale,   F.    and   M.   Hultengren.    1972.   Toluene   exposure.     II.
Psycho-physiological  functions.   Work   Environ.  Health.    9(3):   131-139.
(CHed In U.S. EPA, 1983b)

Greenburg, L., M.R. Mayers,  H.  Helmann  and  S.  MoskowHz.  1942.   The effects
of  exposure  to   toluene  In  Industry.   J.  Am.  Med. Assoc.   118:  573-578.
(CHed 1n U.S. EPA, 1984)

Hannlnen,  H.,  L. Eskellnen,  K.  Husman and M.  Nurmlnen.    1976.   Behavioral
effects of  long-term  exposure to a  mixture of organic solvents.  Scand.  J.
Work Environ.  Health.   2(4): 240-255.  (CHed  1n U.S.  EPA, 1984)
                                     -22-

-------
Hansch,  C.  and  A.J.  Leo.   1981.   Medchem.  Project  Issue  No.  19,  Pomona
College, Claremont, CA.

Hudak,  A.  and 6.  Ungvary.   1978.   Embryotoxlc effects  of  benzene and  Its
methyl derivatives: Toluene  and xylene.   Toxicology.   11:  55.

Ikeda,  M.   1974.   Reciprocal  metabolic  Inhibition of  toluene  and  trlchloro-
ethylene in vivo  and jm  vitro.    Int.  Arch.  Arbeltsmed.   33(2):  125-130.
(Cited  1n U.S. EPA, 1984)

Jenkins, L.J., Jr.,  R.A. Jones and  J.  Siege!.   1970.  Long-term  Inhalation
screening studies  of benzene,  toluene,  o-xylene and  cumene  on  experimental
animals.  Toxlcol. Appl.  Pharmacol.  16:  818-823.  (Cited  1n U.S.  EPA,  1984)

Keane,  J.R.   1978.   Toluene  optic neuropathy.   Ann. Neurol.   4(4):  390.
(Cited  1n U.S. EPA, 1984)

Kelly,  T.W.   1975.  Prolonged  cerebellar  dysfunction associated with  paint
sniffing.  Pediatrics.  56:  605-606.  (Cited 1n  U.S.  EPA,  1984)

Knox,  J.W.  and  J.R.  Nelson.    1966.   Permanent encephalopathy from  toluene
Inhalation.   N. Engl. J.  Med.   275: 1494-1496.  (Cited In  U.S. EPA,  1984)

Litton  B1onet1cs,  Inc.  1978a.   Teratology  Study  In  Rats.   Toluene.   Final
Report.  Submitted  to the  American  Petroleum Institute,  Washington, DC,  1n
January, 1978.   LBI  Project No. 20698-4.  Kensington, MD.  17 p.   (Cited  In
U.S. EPA, 1984)
                                     -23-

-------
Litton Blonetlcs,  Inc.   1978b.  MutagenicHy  Evaluation  of Toluene.   Final
Report.  Submitted  to  the American  Petroleum  Institute,  Washington, DC,  in
May, 1978.  LBI  Project  No.  20847.   Kensington, MD.  150 p.   (Cited  in  U.S.
EPA, 1984)

Mackay,  0.  and A.T.K.  Yeun.   1983.   Mass transfer  coefficient  correlations
for  volatilization  of  organic  solutes from water.   Environ.  Sci.  Technol.
17: 211-217.

Mackay,  D., A.  Bolera,  D.W.  Chan and  W.Y. Shiu.   1982.   Vapor  pressure  cor-
relations   for   low-volatility  environmental   chemicals.    Environ.   Sci.
Technol.   16:  645-649.

Malm,  6.  and  U.  Lying-Tunell.   1980.   Cerebellar  dysfunction related  to
toluene, sniffing.   Acta.  Neurol.  Scand.   62(3):   188-190.   (Cited  in  U.S.
EPA, 1984)

Matsushita, T.,  Y.  Arimatsu,  A.  Ueda, K. Sutoh  and  S.  Nomura.   1975.  Hema-
tological  and  neuro-muscular   response of  workers  exposed  to  low concentra-
tion of  toluene vapor.   Ind. Health.   13: 115.   (Cited in U.S.  EPA,  1984)

McNabb,  J.F.,  B.H.  Smith and J.T.  Wilson.  1981.   B1odegradat1on of toluene
and  chlorobenzene  in  soil and groundwater.   81st  Annual Meeting of  the Am.
Soc. Microbiol., Dallas, TX.  March 1-6.   p.  213.
                                     -24-

-------
Mortelmans, K.E. and  E.S.  Rlcclo.   1980.  in vitro  microbiological  genotox-
1c1ty assays  of toluene.   Prepared by  SRI  International,  Menlo Park,  CA,
under  Contract  No.   68-02-2947.    U.S.  EPA,  Research  Triangle  Park,  NC.
(Cited 1n U.S. EPA, 1984)

Morval,   V.  and  6.  Ungvary.   1979.   Effects   of  simultaneous  alcohol  and
toluene  poisoning  on  the  cardiovascular  system  of  rats.   Toxlcol.  Appl.
Pharmacol.  50(3):  381-389.  (Cited In  U.S.  EPA,  1984)

Munchlnger, R.   1963.   Oer Nachwels central  nervoser  Storungen  be1  Losung-
smlttel   exponlerten  Arbeltern.    Excerpta   Medlca  Series,   Madrid;   16-21.
2(62): 687-689.  (Cited 1n U.S. EPA, 1984)

Nawrot,  P.S. and R.E.  Staples.   1979.   Embryo-fetal  toxldty  and  teratogeni-
dty of benzene  and  toluene In the mouse.  Teratology.   19:  41A.   (CHed  In
U.S. EPA, 1984)

Nestmann,  E.R.,  G.G.-H.   Lee,  T.I. Matula,  6.R.   Douglas  and J.C.  Mueller.
1980.  Mutagen1c1ty  of constituents Identified  In  pulp  and  paper mill  ef-
fluents   using the  Salmonella/mammal1an-m1crosome  assay.   Mutat.  Res.   79:
203-212.   (CHed In U.S.  EPA,  1984)

NIOSH  (National  Institute  for   Occupational   Safety   and  Health).    1973.
Criteria   for   a Recommended   Standard...Occupational  Exposure  to  Toluene.
Final Report.   Contract   No.  HSM-99-72-118.   NTIS  PB-222-219/8.   (CHed  In
U.S. EPA, 1984)
                                     -25-

-------
Nomlyama,  K.  and  H.   Nomlyama.   1974.   Respiratory  retention,  uptake  and
excretion  of   organic   solvents  1n   man.    Benzene,  toluene,   n-hexane,
tMchloroethylene,   acetone,  ethyl  acetate and  ethyl  alcohol.   Int.  Arch.
ArbeHsmed.  32(1-2):  75-83.   (Cited  1n U.S.  EPA,  1984)

Ogata,  M.  and  T.   Fuj11.   1979.   Urinary excretion  of  hlppurlc  acid  and
m-methylh1ppur1c add  after  administration of  toluene and m-xylene  mixture
to rats.   Int.  Arch.  Occup.  Environ.  Health.   43(1):  45-51.   (Cited  1n  U.S.
EPA, 1984)

Ogata, M.  and  Y. Mlyake.   1978.   Disappearance of aromatic hydrocarbons  and
organic  sulfur  compounds   from  fish flesh  reared in  crude oil  suspension.
Water Res.  12: 1041-1044.

Ogata,  M.,  K.  Tomokunl  and  Y.  Takatsuka.   1979.    Urinary  excretion  of
hlppuric  add  and  m- or  p-methylh1ppuric  add   In  the  urine  of  persons
exposed  to vapors of  toluene  and m- or p-xylene  as  a  test  of  exposure.   Br.
J. Ind. Med.   27(1): 43-50.  (Cited in  U.S. EPA,  1983b)

Parmegglana,  L. and C. Sassl.  1954.   Occupational risk of  toluene:  Environ-
mental  studies  and clinical  Investigations  of  chronic Intoxication.   Med.
Lavoro.  45:  475483.  (Hal.)   (Cited 1n U.S.  EPA, 1983b)

Pryor,  G.T.,  J.  Dickinson,  R.A.  Howd  and   C.S.   Rebert.   1983a.   Neuro-
behavloral effects  of subchronlc  exposure of  weanling rats  to toluene  or
hexane.   Neurobehav.  Toxicol. Teratol.   5(1): 47-52.   (Cited  in U.S.  EPA,
1984)
                                     -26-

-------
Pryor, 6.T.,  J.  Dickinson,  R.A.  Howd  and C.S.  Rebert.   1983b.   Transient
cognitive deficits and  high-frequency  hearing loss 1n weanling  rats  exposed
to  toluene.   Neurobehav.  Toxlcol.  Teratol.   5(1):  53-57.   (Cited  In  U.S.
EPA, 1984)

Pyykko,  K.,  H.  Tahtl  and H.  Vapaatalo.    1977.   Toluene concentrations  1n
various  tissues  of  rats after  Inhalation and  oral  administration.   Arch.
Toxlcol.   38: 169-176.  (Cited 1n  U.S.  EPA, 1984)

Rouskova, V.  1975.   Photic  stimulation 1n  early diagnosis  of  the effects of
some  harmful Industrial  substances  on  the  central  nervous  system.   Int.
Arch. Arbeltsmed.   34(4): 283-299.  (Cited 1n U.S. EPA,  1983b)

Sasa,  M.,  S. Igarashl,  T.  M1yazak1,  K.  Mlyazaki  and  S.  and  Nakano.   1978.
Equilibrium  disorders  with  diffuse  brain  atrophy  1n   long-term  toluene
sniffing.   Arch.  Otorhlnolaryngol.   221(3):  163-169.   (Cited  1n  U.S.  EPA,
1984)

Sato,  A.  and  T.  Nakajima.   1979.    Dose-dependent  metabolic  Interaction
between  benzene and  toluene  jjn  vivo and j_n vitro.  Toxlcol.  Appl. Pharmacol.
48(2): 249-256.   (Cited in U.S. EPA, 1984)

Satran,  R.  and  V. Dodson.   1963.  Toluene  habitation  — Report of  a  case.
N. Engl.  J. Med.  263(13): 219-220.   (Cited in U.S. EPA,  1984)
                                     -27-

-------
Seppalalnen, A.M.,  K.  Husman  and C.  Martenson.   1978.   Neurophyslologlcal



effects of  long-term  exposure to a  mixture  of organic  solvents.   Scand.  J.



Work Environ. Health.   4(4):  304-314.  (Cited In U.S.  EPA,  1984)







Shlgeta, S., H.  Alkawa and T.  Mlsawa.   1982.  Effects  of  maternal  exposure



to  toluene  during pregnancy  on  mouse  embryos and  fetuses.   Tokai J.  Exp.



CUn. Med.   7(2): 265-270.  (Cited 1n U.S.  EPA, 1984)







Singh,  H.B., L.3.  Salas,  A.J.  Smith  and  H.   Shlgelshl.  1981.   Measurements



of  some  potentially   hazardous   organic  chemicals  In  urban  environments.



Atmos. Environ.  15:  601-612.







Smith,  J.N., R.H.  Smithies and  R.T.  Williams.  1954.    Studies  1n  detoxlca-



tion, 55.   The metabolism of  alkylbenzenes,  a/Glucuron1c acid excretion fol-



lowing  the  administration of  alkylbenzenes;  b/E!1m1nat1on  of  toluene  1n  the



expired air of  rabbits.  Blochem. J.   56:  317-320.   (Cited  In U.S.  EPA, 1984)







Smyth,  H.F., Jr.,  C.S.  Well,  J.S. West and  C.P. Carpenter.  1969.   Explora-



tion  of joint  toxic action:  Twenty-seven  Industrial  chemicals  Intubated  1n



rats  In all  possible  pairs.   Toxlcol.  Appl.  Pharmacol.    14(2):  340-347.



(Cited  In U.S.  EPA, 1984)







Snow, L., P. MacNalr  and  B.C. Casto.  1981.   Mutagenesls  testing  of toluene



1n Salmonella strains TA100 and  TA98.  Prepared  for  the U.S.  EPA by Northrup



Services, Inc.,  P.O.  Box  12313,  Research  Triangle  Park, NC   27709.   (Cited



1n U.S. EPA, 1984)
                                     -28-

-------
SRC  (Syracuse  Research  Corporation).   1981.    Health  Risk  Assessment  for

Toluene.    Draft report  prepared  under  Contract   68-03-377  for  U.S.  EPA,

Research  Triangle Park,  NC.   (Cited In U.S.  EPA,  1983b)




Suhr, E.   1975.  Comparative Investigation of the State of  Health  of  Gravure

Printers   Exposed  to  Toluene.   Gesellschaft  zur   Forderung  des  Tlefdrucks


E.V., Welsbaden,  Federal  Republic  of  Germany.   92 p.  (Cited  1n U.S.  EPA,
                                                 <

1983b)




Tarsh, M.J.   1979.  Sch1zophren1form  psychosis  caused  by  sniffing  toluene.

J. Soc.  Occup. Med.  29(4):  131-133.  (Cited 1n U.S. EPA,  1984)




Tatral,  E., K.  Rodlcs  and  G. Ungvary.  1980.  Embryotoxlc  effects  of simul-

taneously  applied   exposure  of  benzene  and  toluene.   Folia  Morphologlca.


28(3): 286-289.  (Cited 1n U.S.  EPA, 1984)




Ungvary,  G.,  S.  Manyal,  E.  Tatral, et  al.   1980.   Effect  of  toluene  Inhala-

tion  on  the  liver  of  rats — Dependence  on  sex, dose and  exposure  time.   J.

Hyg.  Ep1dem1ol. Nlcroblol. Immunol.  24: 242-252.  (Cited  1n U.S. EPA, 1984)




Ungvary,  G.,  E. Tatral, M.  LoMncz and G.  Barcza.   1983.   Combined  embryo-

toxic  action   of  toluene,  a widely  used  Industrial chemical  and  acetyl-

sallcylic add  (aspirin).  Teratology.  27(2): 261-269.   (Cited  In  U.S.  EPA,

1984)
                                     -29-

-------
U.S.  EPA.   1980.   Guidelines  and  Methodology  Used  In  the  Preparation  of



Health  Effects   Assessment  Chapters  of  the  Consent   Decree  Water  Quality



Criteria.  Federal Register.  45:79347-79357.







U.S.  EPA.   1982a.   Health  and  Environmental  Effects  Profile for  Toluene.



Environmental  Criteria and Assessment Office, Cincinnati, OH.







U.S. EPA.  1982b.   Health Effects  Assessment Document  for Toluene.   Environ-



mental Criteria and Assessment Office, Cincinnati, OH.   Internal  draft.







U.S. EPA.  1983a.   Methodology and  Guidelines  for Reportable  Quantity Deter-



minations  Based  on  Chronic Toxldty  Data.   Prepared  by  the  Environmental



Criteria and Assessment Office, Cincinnati,  OH,  OHEA  for the  Office of Solid



Waste and Emergency Response,  Washington, DC.







U.S.  EPA.   1983b.   Reportable  Quantity  for  Toluene.   Prepared  by  the



Environmental  Criteria  and  Assessment  Office,  Cincinnati, OH, OHEA  for  the



Office of Solid Waste and Emergency Response, Washington, DC.







U.S. EPA.  1984.   Drinking  Water  Criteria  Document  for  Toluene.   Prepared by



the  Environmental  Criteria  and Assessment  Office,  Cincinnati, OH,  OHEA  for



the Office of  Drinking Water,  Washington, DC.  External  review draft.







U.S. EPA.  1985.   Drinking  Water  Criteria  Document  for  Toluene.   Prepared by



the  Environmental  Criteria  and Assessment  Office,  Cincinnati, OH,  OHEA  for



the Office of  Drinking Water,  Washington, DC.  Final draft.
                                     -30-

-------
Van Aalst, R.M., A.C. Besemer, T. Lems and  H.  Nleboer.   1980.   Photochemical
conversion of aromatic hydrocarbons under  simulated  tropospherlc  conditions.
Comm. Eur. Communities Eur.  6621,  Proc.  Eur. Symp.  Phys-Chem.  Behav.  Atmos.
Pollut.   1: 136-149.

von  Oettlngen,  W.F.,  P.A.  Neal and O.D.  Donahue.    1942a.  The toxldty  and
potential  dangers  of toluene  - Preliminary  report.  J.  Amer. Med.  Assoc.
118: 579-584.  (Cited In U.S. EPA,  1983b)

von  Oettlngen,  W.F.,  P.A.  Neal, D.O.  Donahue,  et  al.   1942b.  The  toxlclty
and  potential dangers of toluene, with special  reference to  Us maximal  per-
missible  concentration.   U.S.  Publ.  Health  Serv.  Publ.  Health Bull.  No.
279.  50 p.  (Cited In U.S.  EPA, 1983b)

Waldron,  H.A.,  N.  Cherry and  J.D.  Johnston.   1983.   The  effects  of  ethanol
on  blood  toluene concentrations.   Int. Arch.  Occup.  Environ.  Health.   51(4):
365-369.   (Cited 1n U.S. EPA, 1984)

Welsenberger,  B.L.   1977.   Toluene  habltuatlon.    J.   Occup.  Med.   19(8):
569-570.   (Cited In U.S. EPA, 1984)

Wilson,  J.T.,  C.G. Enfleld,  W.J.  Dunlap,  R.L.  Cosby,  D.A.  Foster and  L.B.
Baskln.   1981.  Transport and  fate  of  selected  organic  pollutants In  a sandy
soil.  J.  Environ. Qual.  10: 501-506.
                                     -31-

-------
Wilson,  3.T.,  J.F.  McNabb,  R.H.  Wilson and  M.J.  Noonan.  1983.   Blotrans-
formatlon  of   selected   organic   pollutants  1n  groundwater.    Dev.   Ind.
M1crob1ol.  24:  225-233.

Wilson,  R.H.    1943.   Toluene  poisoning.    J.  Am.  Med.  Assoc.   12:  1106.
(Cited 1n U.S. EPA,  1983b)

Wolf,  M.A.,  V.K. Rowe,  D.D. McColllster,  R.L.  Holllngsworth  and F.  Oyen.
1956.   Tox1colog1cal   studies  of  certain  alkylated benzenes  and  benzene.
Arch. Ind. Health.  14: 387.  (Cited 1n U.S. EPA,  1984)
                                     -32-

-------
                                                 APPENDIX



                                         Summary Table for Toluene
Species
Inhalation
AIS rat
AIC rat
Maximum
composite human
, score
CO
CO
1
Oral
AIS rat
AIC rat
Experimental
Dose/Exposure

1130 mg/m3
1130 mg/m3
300 ppm (1130 mg/m3)
occupational (RV(j=1)
590 mg/kg
1130 mg/m3
Effect Acceptable Intake
(AIS or AIC)

NOAEL 104.9 mg/day
NOAEL 104.9 mg/day
CNS dysfunction 7
(RVe=7)
NOEL 30 mg/day
NOAEL 20.3 mg/day*
Reference

CUT, 1980
CUT, 1980
SRC, 1981;
U.S. EPA,
Wolf et al
1956
CUT, 1980



1983b
* »

*Th1s oral AIC Is based on an Inhalation  study  as  proposed  by  U.S.  EPA  (1984).

-------